La secuenciación de ARN de una sola célula revela TOP2A como un factor clave de la progresión del carcinoma hepatocelular
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La topoisomerasa II alfa (TOP2A) está regulada al alza en el carcinoma hepatocelular (HCC) y conduce a la progresión tumoral. La eliminación de TOP2A inhibe la proliferación, migración e invasión de las células de HCC, ofreciendo un objetivo terapéutico potencial para el tratamiento de HCC.
Área De La Ciencia
- En el campo de la oncología
- Biología molecular
- La bioinformática
Sus Antecedentes
- El carcinoma hepatocelular (HCC) sigue siendo un desafío significativo para la salud mundial con estrategias terapéuticas efectivas limitadas.
- Comprender los mecanismos moleculares que impulsan la progresión del CHC es crucial para desarrollar nuevos tratamientos.
Objetivo Del Estudio
- Investigar las funciones biológicas y el papel oncogénico de la topoisomerasa II alfa (TOP2A) en el CHC.
- Explorar el TOP2A como un potencial biomarcador de diagnóstico y objetivo terapéutico para el CHC.
Principales Métodos
- Análisis bioinformático y secuenciación de ARN de una sola célula (scRNA-seq) de tejidos HCC.
- La PCR cuantitativa (QPCR) y el Western Blotting para validar la expresión de TOP2A y la eficiencia de eliminación del siRNA.
- Ensayos funcionales in vitro que incluyen CCK8, cicatrización de heridas, Transwell y citometría de flujo para evaluar la proliferación, migración, invasión y apoptosis.
Principales Resultados
- TOP2A fue significativamente regulado en los tejidos de HCC y se correlacionó con un mal pronóstico.
- La eliminación del TOP2A mediada por siRNA (> 70% de eficiencia) inhibió significativamente la proliferación, invasión y migración de las células de HCC, al tiempo que promovió la apoptosis.
- Los datos de scRNA-seq sugirieron que TOP2A promueve la diferenciación de Tmem a Tex a través del eje SPP1-CD44, contribuyendo potencialmente a la evasión inmune.
Conclusiones
- TOP2A es un factor oncogénico crítico y un biomarcador pronóstico independiente en el CHC.
- La orientación a TOP2A puede inhibir la progresión del HCC y puede superar la evasión inmune.
- TOP2A representa un objetivo terapéutico prometedor para la inmunoterapia del CHC.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...